Results 161 to 170 of about 143,755 (261)

Factors Affecting Surgical Outcomes Following Rotationplasty in Paediatric Sarcoma: A Literature Review

ANZ Journal of Surgery, EarlyView.
Rotationplasty is a durable limb‐salvage option for paediatric lower‐limb sarcoma. Across 58 studies and 1,217 patients, long‐term functional, psychosocial, and quality‐of‐life outcomes were favourable, often surpassing amputation and endoprosthetic reconstruction.
Rachel H. Ko, Stewart Morrison, Daniel J. Wilks   +2 more
wiley   +1 more source

Upper Extremity Deep Vein Thrombosis in Cancer Patients: Clinical Course by Cancer Site. [PDF]

JACC CardioOncol
Espitia O, Guedon AF, Courouve E, Brenner B, López-Núñez JJ, Chopard R, Lorenzo A, Sigüenza P, Truong Nguyen S, Monreal M, RIETE Investigators.   +10 more
europepmc   +1 more source

SURGELLA: A Scoping Review of Impella‐Assisted Hemodynamic Support in High‐Risk Non‐Cardiac Surgery

Artificial Organs, EarlyView.
In selected patients with severe LV dysfunction, Impella‐supported non‐cardiac surgery may provide a temporary hemodynamic bridge to otherwise prohibitive procedures. Published evidence remains limited to a small number of highly selected cases, supporting technical feasibility rather than comparative benefit or generalizable safety.
Hussein Elghazaly, Mohammed Allaf, Areeb Mian, Hanad Ahmed, Alex Gordon‐Weeks, Alexander Tindale, Vasileios Panoulas   +6 more
wiley   +1 more source

Anticoagulation for Cancer Patients in Special Situations: A Narrative Review of Guidelines and Literature. [PDF]

Cancers (Basel)
Sotoca Rubio P, Serrano Domingo JJ, Guerrero Serrano P, Pérez de Aguado Rodríguez P, Barrill Corpa AM, Moreno Doval J, García de Quevedo Suero C, Calvo Pérez JC, González-Merino C, González Martín G, Chamorro Pérez J, Gómez Rueda A, Garrido López P.   +12 more
europepmc   +1 more source

Progress Toward a Portable Artificial Lung: A Systematic Review

Artificial Organs, EarlyView.
Eight portable respiratory assist devices were identified. The CE‐marked MobyBox and the FDA‐approved Breethe OXY‐1 system are in clinical use. Each device is substantially minimized to allow ambulation, but further work is required to address challenges related to anticoagulant management and safe mobilization. Created in BioRender. Svendsen, A. (2026)
Maja Munk Svendsen, Clara Kjær Hendriksen, Lars Folkersen, Peter Juhl‐Olsen, Leila Louise Benhassen, Søren Nielsen Skov   +5 more
wiley   +1 more source

CRRT-miECCO₂R: a step toward integrated multiorgan support. [PDF]

Crit Care
Husain-Syed F, Kryvenko V, Vadász I.
europepmc   +1 more source

Multifactorial Nature of Childhood Stroke Presents a Major Challenge for Diagnosis and Management: A Population‐Based Study From Southern Finland

Acta Paediatrica, EarlyView.
ABSTRACT Aim Childhood ischemic stroke is rare but causes substantial long‐term morbidity, and its heterogeneous aetiology complicates timely diagnosis and management. Methods We conducted a retrospective population‐based observational study using hospital data and chart review to describe diagnostics, treatment and outcomes of ischemic stroke in ...
Jussi V. Leinonen, Samu Kurki, Siina Pamilo, Juho Immonen, Juha Knuuttila, Matti Hero, Mia Westerholm‐Ormio, Pirjo Isohanni, Miika Koskinen   +8 more
wiley   +1 more source

A Retrospective Study of Preventive Anticoagulant Therapy Among Trauma Patients in Yichang Area Through Clinical Data Review and Clinician Survey. [PDF]

Int J Gen Med
Chen S, Zou M, Chen M, Feng M, Wan P.
europepmc   +1 more source

Successful management of cavernous sinus thrombosis without anticoagulation: a neuro-ophthalmologic case report. [PDF]

Front Neurol
Wang XO, Hu CZ, Niu YM, Tian W.
europepmc   +1 more source

Janus kinase inhibitors after ruxolitinib failure in myelofibrosis: A systematic review and pooled analysis of phase 3 efficacy and integrated safety across clinical trials and real‐world evidence

British Journal of Haematology, EarlyView.
Summary Ruxolitinib remains first‐line standard of care for symptomatic myelofibrosis, but resistance/intolerance develops in most patients. Three Janus kinase inhibitors (JAKis) have entered the post‐ruxolitinib space via distinct pivotal trials. We systematically searched prospective trials evaluating JAKi in refractory adults with myelofibrosis ...
Andrea Duminuco, Patrick Harrington, Elena Torre, Hillary Catellani, Novella Pugliese, Matteo Pacilli, Annalisa Santisi, Arianna Sbriglione, Giuseppe A. Palumbo   +8 more
wiley   +1 more source